SEC Search Search From : Home > Search > Search Results search: Public Information System Debenture Prospectus ( 1,293 ) Equity Prospectus ( 418 ) Investor Alert ( 309 ) Form 246-2 : Reports on

- Translation- June 11, 2019 Subject: Notification the Acquisition of share of BS Myco Biotech Company Limited. (Additional Information Memorandum Concerning the Acquisition of Assets) To: Director and Manager

Facility, Dayton Facility and Chocolate Bayou Facility) ** Equity Acquisitions * Asset Acquisitions 8 6.3 Summary of the Financial Information and Business Operating Results on Proforma* basis Since it is a

1,105,365.03 785,060,391.00 Other non-current assets 28,704.25 20,386,543.00 Total assets 1,398,180.07 993,025,621.00 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities and other current liabilities

103.43 102.12 (1.31) (1.27%) Liabilities and equity Current liabilities Amount due to related companies 0.34 0.01 (0.33) (97.56%) Current portion of financial lease liabilities 0.60 0.47 (0.13) (21.26

: 1. Digital content via telecommunication channels 2. Information technology solutions for electronic devices 3. Online advertising for products and services. The details of Services income and Cost of

per share (information from SETSMART at www.setsmart.com of the SET). In this regard, the Allocation and Offering of the Newly Issued Ordinary Shares of the Company under the Debt to Equity Conversion

offering1. In this regard, the Company shall disclose the following information: (1) Spending of the money obtained from each offering of equity or debt securities2. Spending Objectives Amount of Spent Money

cases, disclose at least the amount of money and the spending duration. 2 Disclosure of information related to spending of money obtained from offering of equity or debt securities applies to the Company

” B. Key Financial ratio, provide the following information; 1. net debt to EBITDA ratio 2. interest coverage ratio 3. debt service coverage ratio 4. debt to equity ratio 5. current ratio 6. bill of